648 370

Cited 0 times in

고지방 및 고포도당 조건에서 배양한 근육 세포의 지방산 대사에 미치는 PPAR-α와 PPAR-γ agonist의 효과

Other Titles
 Effects of PPAR-α and -γ Agonists on Fatty Acid Metabolism of Muscle Cells in Hyperlipidemic and Hyperglycemic Conditions 
Authors
 이용직  ;  조정산  ;  김수경  ;  김혜진  ;  심완섭  ;  안철우  ;  이현철  ;  차봉수 
Citation
 Journal of Korean Diabetes Association (당뇨병), Vol.30(5) : 324-335, 2006 
Journal Title
 Journal of Korean Diabetes Association (당뇨병) 
ISSN
 2233-6079 
Issue Date
2006
Keywords
Fatty acid oxidation ; Hyperglycemic ; Hyperlipidemic ; H9c2 cell ; Malonyl-CoA decarboxylase (MCD) ; PPAR-α agonist ; PPAR-γ agonist ; Rosiglitazone ; Skeletal muscle cell ; WY14,643
Abstract
Background: Studies for the regulation of fatty acid metabolism are deficient relatively in skeletal muscle and heart. The investigations in pathological conditions for malonyl-CoA decarboxylase (MCD) and for the relation of MCD and PPAR-α·-γ agonists are insufficient in particular. Methods: In the current study, fully differentiated H9c2 muscle cells were exposed to pathological conditions such as hyperlipidemic (0.1 mM Palmitate) and hyperglycemic (16.5 mM Glucose) condition with 5 uM PPAR-γ agonist (rosiglitazone) and 10 uM PPAR-α agonist (WY14,643) and then experiments such as MCD activity assay, MCD real-time RT-PCR, MCD reporter gene assay, MCD Western blotting, PPAR-α Western blotting, and palmitate oxidation test were carried out. Results: Only PPAR-α agonist increased MCD activity. In the result of real-time RT-PCR, both PPAR-α and PPAR-γ agonists elevated MCD mRNA expression in hyperlipidemic condition. MCD protein expression was decreased in hyperlipidemic condition, however, increased in rosiglitazone, or WY14,643 treated conditions. Rosiglitazone, and WY14,643 treated groups showed incresed MCD protein expression in hyperglycemic condition. Hyperlipidemic control group and PPAR-α·-γ agonists treated groups presented about 3.8 times more increased palmitate oxidation level than normolipidemic control group in hyperlipidemic condition. PPAR-α agonist treated group showed 49% more increased palmitate oxidation rate than hyperlipidemic control group in primary cultured rat skeletal muscle cells. The amount of palmitate oxidation from differentiated H9c2 muscle cells that had overexpressed PPAR-α structural genes was more increased than control group. Conclusion: This study suggests that PPAR-α agonist ameliorates the defects induced by hyperlipidemic condition through the regulation of MCD. In summary, a closely reciprocal relation among PPAR-α agonist, MCD, and fatty acid oxidation existed distinctly in hyperlipidemic condition, but not in hyperglycemic condition.
Files in This Item:
T200601447.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Ahn, Chul Woo(안철우) ORCID logo https://orcid.org/0000-0003-3733-7486
Lee, Hyun Chul(이현철)
Cha, Bong Soo(차봉수) ORCID logo https://orcid.org/0000-0003-0542-2854
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/110438
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse